Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123834 | 0.83 | MMP3 (0.48) | CYP11B2KIF11RHEBMMP3HRH4 | |
| SCHEMBL6466819 | 0.81 | HRH4 (0.52) | CYP11B1CYP11B2CYP2C9CYP2C19KIF11 | |
| SCHEMBL11296944 | 0.80 | GRM5 (0.51) | GRM5KDM4ERECQL | |
| SCHEMBL4718621 | 0.75 | KIF11 (0.42) | KDM4EKIF11F2RL3 | |
| SCHEMBL18123835 | 0.74 | SQOR (0.38) | CYP11B1CYP11B2KDM4ECYP2C9CYP2C19 | |
| SCHEMBL1029236 | 0.74 | SLC6A4 (0.58) | — | |
| SCHEMBL24909701 | 0.73 | TTR (0.44) | GRM5RECQL | |
| SCHEMBL18123833 | 0.70 | MAPKAPK2 (0.46) | KDM4ECYP2C9CYP2C19CYP1A1CYP1B1 | |
| SCHEMBL26901810 | 0.69 | RECQL (0.43) | GRM5KDM4ERECQL | |
| SCHEMBL3611983 | 0.69 | MMP3 (0.64) | CYP11B2KIF11MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190055250-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-02-21 | — | — | US | disclosed |
| US-9944647-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | CYP11B1 445/4885CYP11B2 537/4885GRM5 1716/4885 |
| US-20190055250-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | CYP11B1 445/4885CYP11B2 537/4885GRM5 1716/4885 |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | CYP11B1 445/4885CYP11B2 537/4885GRM5 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.